Current Survey on Chemotherapy-Related Myelosuppression and Clinical Management in Chinese County-level Tumor Patients
NCT06641934 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000
Last updated 2024-10-16
Summary
Current Survey on Chemotherapy-Related Myelosuppression and Clinical Management in Chinese County-level Tumor Patients
Conditions
- Myelosuppression
Interventions
- OTHER
-
No intervention; Observational study
No intervention
Sponsors & Collaborators
-
Xinxiang Central Hospital of Henan province
collaborator UNKNOWN -
Linzhou People Hospital
collaborator UNKNOWN -
Inner Huang County Traditional Chinese Hospital
collaborator UNKNOWN -
Changyuan People Hospital
collaborator UNKNOWN -
Huojia County People Hospital
collaborator UNKNOWN -
Huojia County Alliance Hospital
collaborator UNKNOWN -
Qinyang People Hospital
collaborator UNKNOWN -
Xinan County People Hospital
collaborator UNKNOWN -
Henan Hongli Hospital
collaborator UNKNOWN -
Army Hospital of the 83rd Army
collaborator UNKNOWN -
Anyang Cancer Hospital
collaborator UNKNOWN -
Puyang Hospital of Traditional Chinese Medicine
collaborator UNKNOWN -
Puyang Huimin Hospital
collaborator UNKNOWN -
Hebi People Hospital
collaborator UNKNOWN -
The Second People Hospital of Xinxiang Henan
collaborator UNKNOWN -
The First Affiliated Hospital of Xinxiang Medical College
lead OTHER
Principal Investigators
-
Ji YH yinghua, Dr. · The First Affiliated Hospital of Xinxiang Medical College
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-10-20
- Primary Completion
- 2025-10-20
- Completion
- 2025-12-20
Countries
- China
Study Locations
More Related Trials
-
Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
NCT05261438 ·Status: COMPLETED
-
Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic
NCT06497543 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
The Efficacy and Safety of Adjuvant Immunotherapy After Pathological Complete Response Following Neoadjuvant Chemoimmunotherapy in Patients with Resectable NSCLC
NCT06243679 ·Status: ACTIVE_NOT_RECRUITING
-
Efficacy and Safety of a Third-Course of Neoadjuvant Immunochemotherapy Combined With SBRT in Locally Advanced Head and Neck Squamous Cell Carcinoma Patients With Stable Disease After Two Treatment Courses: A Single-Arm Exploratory Study
NCT06722495 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
An Observational Clinical Study Plan on the Effects of Radiotherapy on the Immune System of Patients With Malignant Tumors.
NCT06202534 ·Status: RECRUITING
-
AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer
NCT06080854 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC
NCT04189094 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases
NCT06440954 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy With Cryoablation in NSCLC
NCT06483009 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
The Role of Adding Concurrent Chemotherapy to IMRT in the Treatment of Stage II Nasopharyngeal Carcinoma
NCT02116231 ·Status: UNKNOWN ·Phase: PHASE2
-
Radiotherapy to All Residual Lesions After Chemoimmunotherapy
NCT06479473 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer
NCT06861712 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
TPExtreme Induced Chemotherapy Followed by Surgery and Radiotherapy in the Oral Carcinoma.
NCT05872880 ·Status: RECRUITING
-
Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)
NCT06130332 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients
NCT05378334 ·Status: RECRUITING ·Phase: NA
-
Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal Carcinoma
NCT02621970 ·Status: UNKNOWN ·Phase: PHASE3
-
A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma
NCT07062484 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Pharmacokinetics and Tolerancebility Studies of Gentuximab Injection in the Treatment ofPatients With Late Recurrence of Metastatic Solid Tumors in China
NCT03313219 ·Status: UNKNOWN ·Phase: PHASE1
-
Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Cindilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer
NCT05312840 ·Status: UNKNOWN ·Phase: PHASE4
-
Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma
NCT01271439 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China
NCT01863485 ·Status: COMPLETED ·Phase: PHASE1
-
Chronomodulated Chemotherapy Followed by Concurrent Chemo-radiotherapy With IMRT in the Treatment of Advanced Nasopharyngeal Cancer
NCT02937519 ·Status: UNKNOWN ·Phase: PHASE2
-
Narlumosbartmab Combined With Neoadjuvant Chemotherapy in Bone-derived Malignancies With Osteolytic Lesions and Multinucleated Giant Cells
NCT06302465 ·Status: RECRUITING ·Phase: NA
-
The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC
NCT06182657 ·Status: RECRUITING
-
Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC
NCT06718309 ·Status: RECRUITING ·Phase: PHASE2